Mobile

A phase I/II, observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-005943-24

A phase I/II, observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy male subjects aged 10-18 years

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To evaluate 1 month after the third dose (i.e. at Month 7), the immune responses to the candidate HPV-16/18 vaccine (as determined by anti-HPV-16/18 ELISA) in healthy male subjects aged 10-18 years old.

Critère d'inclusion

  • In female subjects from 10 years of age onwards for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities including ASC-US, cervical intraepithelial neoplasia (CIN) and pre-cancerous lesions caused by oncogenic human papillomaviruses (HPV). In male subjects from 10 years of age onwards for the prevention of transmission of human papillomaviruses (HPV) causing persistent infections and related clinical outcomes

Liens